These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23943896)

  • 1. Documenting the benefits and cost savings of a large multistate cancer pathway program from a payer's perspective.
    Kreys ED; Koeller JM
    J Oncol Pract; 2013 Sep; 9(5):e241-7. PubMed ID: 23943896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost drivers for breast, lung, and colorectal cancer care in a commercially insured population over a 6-month episode: an economic analysis from a health plan perspective.
    Sagar B; Lin YS; Castel LD
    J Med Econ; 2017 Oct; 20(10):1018-1023. PubMed ID: 28581874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of cancer supportive care pathways compliance on emergency department visits and hospitalizations.
    Kreys ED; Kim TY; Delgado A; Koeller JM
    J Oncol Pract; 2014 May; 10(3):168-73. PubMed ID: 24839275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.
    Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
    Oncologist; 2019 Sep; 24(9):1209-1218. PubMed ID: 30796156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does reimbursement influence chemotherapy treatment for cancer patients?
    Jacobson M; O'Malley AJ; Earle CC; Pakes J; Gaccione P; Newhouse JP
    Health Aff (Millwood); 2006; 25(2):437-43. PubMed ID: 16522584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients and Physicians Can Discuss Costs of Cancer Treatment in the Clinic.
    Kelly RJ; Forde PM; Elnahal SM; Forastiere AA; Rosner GL; Smith TJ
    J Oncol Pract; 2015 Jul; 11(4):308-12. PubMed ID: 26015459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genentech caps cost of cancer drug for some patients.
    Pollack A
    N Y Times Web; 2006 Oct; ():C2. PubMed ID: 17061339
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost variation and savings opportunities in the Oncology Care Model.
    Baumgardner J; Shahabi A; Zacker C; Lakdawalla D
    Am J Manag Care; 2018 Dec; 24(12):618-623. PubMed ID: 30586495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Service setting impact on costs for bevacizumab-treated oncology patients.
    Engel-Nitz NM; Yu EB; Becker LK; Small A
    Am J Manag Care; 2014 Nov; 20(11):e515-22. PubMed ID: 25730350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
    Tscheulin DK; Drevs F
    Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost of care for lung cancer in the first year after diagnosis in Iran.
    Mohagheghi MA; Mousavi-Jarrahi Y; Mosavi-Jarrahi A
    Asian Pac J Cancer Prev; 2011; 12(4):1013-5. PubMed ID: 21790243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Willingness to pay to prevent chemotherapy induced nausea and vomiting among patients with breast, lung, or colorectal cancer.
    Miller PJ; Balu S; Buchner D; Walker MS; Stepanski EJ; Schwartzberg LS
    J Med Econ; 2013 Oct; 16(10):1179-89. PubMed ID: 23919632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physician-based active cost management of oncological therapies reducing pharmaceutical costs by 83.4% in two years without leaving standard of care.
    Jacobs VR; Thoedtmann J; Euler U; Paepke S; Fischer T; Harbeck N; Kiechle M
    Onkologie; 2005 Aug; 28(8-9):441-5. PubMed ID: 16160408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation monitoring by an anticoagulation service is more cost-effective than routine physician care.
    Aziz F; Corder M; Wolffe J; Comerota AJ
    J Vasc Surg; 2011 Nov; 54(5):1404-7. PubMed ID: 21741791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [[How to finance chemotherapy with new cancer drugs?].
    Livartowski A; Beuzeboc P; Le Vu B; Courbard M; Pierga JY; Extra JM; Scholl S; Pouillart P
    Bull Cancer; 2000 Oct; 87(10):745-54. PubMed ID: 11084538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose rounding of chemotherapy in colorectal cancer: an analysis of clinician attitudes and the potential impact on treatment costs.
    Field K; Zelenko A; Kosmider S; Court K; Ng LL; Hibbert M; Gibbs P
    Asia Pac J Clin Oncol; 2010 Sep; 6(3):203-9. PubMed ID: 20887502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay.
    Mittmann N; Earle CC; Cheng SY; Julian JA; Rahman F; Seung SJ; Levine MN
    J Clin Oncol; 2018 Jan; 36(3):238-243. PubMed ID: 29193984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.